IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS - VASC-UC

CHU Amiens-Picardie0 个研究点目标入组 100 人开始时间: 2020年9月14日最近更新: 2020年11月30日

适应症

试验速览

暂无简介。

•-Ulcerative colitis evolving for at least 6 months
•-Patient older than 18 years
•-Initiating a treatment by infliximab, adalimumab, golimumab, vedolizumab or tofacitinib
•-Patient covered by French national health insurance
•-Written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 80
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•-Patients with anti-hypertensive, antiplatelet or lipid-lowering drugs without stable dosage within the 3 months before the study and over the study period.
•- Patients with a cardiovascular event such as myocardial infarction and stroke
•- Diabetic patient
•- Pregnant women or breastfeeding
•--Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)

发起方

CHU Amiens-Picardie